Study Finds Certain Foods Could Cause Nightmares
A study done at the University of Montreal that was published in Frontiers in Psychology finds that certain foods eaten during the evening or late at night may cause nightmares and impact sleep.
The study involved 1,082 participants and 40.2% of them reported that certain foods either helped or hurt their sleep. Also, 5.5% of the participants reported that food impacted their dreams.
The study found that it was plausible that those who both consumed dairy products and had lactose intolerance were more susceptible to "bizarre or disturbing dreams."
Dairy products were only the second-most troublesome thing when it came to bad dreams, though, as desserts and sweets topped the list among respondents.
"The perceived effect of food on dreams was associated with higher nightmare recall and Nightmare Disorder Index scores, with changes being blamed primarily on desserts/sweets (31%) and dairy (22%)," the study said.
As far as lactose-related nightmares are concerned, issues with digesting the dairy products while sleeping could be at the root of the problem. Food allergies and gluten intolerance were also mentioned.
Bloating, gas, diarrhea, abdominal pain and cramping, and nausea and vomiting are all gastrointestinal issues that are symptoms of lactose intolerance, according to the Mayo Clinic.
Researchers also noted that healthier eating — and particularly less eating in the evening — was linked to better dream recall.Study Finds Certain Foods Could Cause Nightmares first appeared on Men's Journal on Jul 1, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings
Definium™ Pace Select ET, a new floor-mounted digital X-ray system, enables access to affordable, high-quality medical imaging technology while easing workflow burdens in high-volume environments This new X-ray system, designed to act as a personal assistant for technologists, provides automation of in-room workflows and motorization of manual, repetitive tasks to increase throughput and reduce technologist learning curve CHICAGO, July 24, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), today announced commercial availability of an advanced floor-mounted digital X-ray system, Definium™ Pace Select ET1, designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability. X-ray exams often serve as the entry point to diagnostic imaging, accounting for 60% of all imaging studies conducted, resulting in an ever-increasing workload for radiologists and technologists2 3. This increased demand, combined with acute staffing challenges where 80% of healthcare organizations are short-staffed and radiology technologists have the highest vacancies3, high burnout levels and work-related injuries, creates critical barriers to providing timely, effective diagnostic imaging for patients in need of X-ray imaging. GE HealthCare's new Definium Pace Select ET solves for many of these challenges by automating manual, repetitive steps and helping to reduce physical strain. The system leverages AI to ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize the patient experience and throughput. "Burdened with the stress and pressure to keep radiology departments running smoothly and profitably, we aim to empower technologists with a system that consistently makes the first image count," said Sharad Sharma, Global General Manager, X-ray, at GE HealthCare. "With its advanced digital capabilities and automation, Definium Pace Select ET allows technologists of all experience levels to deliver consistent high-quality images to serve the full range of anatomies and patient populations." Easy-to-use features allow technologists to focus on patient care Building on the trusted Definium platform from GE HealthCare, the Definium Pace Select ET system brings advanced automation and workflow features to a flexible, floor-mounted system with elevating table, in-room exam control, and common user interface to assist technologists. "This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President & CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging." The Definium Pace Select ET system brings the same high image quality typically seen in more expensive overhead tube suspension (OTS) systems to the affordability focused floor-mounted market. Designed and developed with extensive customer feedback, the system brings: Advanced automation to reduce workflow steps and physically demanding movements for technologists, potentially minimizing work-related injuries. Image variability reduction through the AI-enabled Helix™ Advanced Image Processing to provide consistent high-quality images. Prevention of errors before they occur through automated positioning, protocol selection, patient size (body habitus), and collimation via the Intelligent Workflow Suite, and a quality check prior to radiation exposure. To learn more about the new X-ray system, visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. _______________________________ 1 510(k) cleared. Not CE marked. Cannot be placed on the market or put into service or used with human beings until it has been made to comply with CE marking and/or regulatory approval. Not all features available in all markets. 2 MV 2019 X-ray CR / DR Market Outlook Report) page 9, 37 3 Pearson, Dave. "Radiology techs in especially high demand as 85% of hospitals seek 'allied' health workers", 23 Oct. 22. View source version on Contacts GE HealthCare Media Contact: Katie ScrivanoM +1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
2 hours ago
- Fox News
The new world of medicine: AI doctors
Doctronic founders Dr. Adam Oskowitz and Matt Pavelle discuss their new AI tool to help users better 'understand their health' and communicate with their doctors on 'America Reports.'
WebMD
2 hours ago
- WebMD
FDA OKs New Steroid-Free Skin Cream for Hand Eczema
July 24, 2025 – The FDA has approved a new treatment as the first and only skin cream for a specific type of hand eczema that affects about 1 in every 10 people globally. The cream, sold under the name Anzupgo, contains a new drug called delgocitinib and is for adults with long-term or chronic hand eczema (CHE), especially if steroid creams don't help or aren't a good option. CHE is a type of eczema that affects hands and wrists, causing the skin to become dry, itchy, sore, blistered, thick, or swollen. It can last for at least three months and flares up at least twice a year. CHE develops when the skin's protective barrier is damaged, leading to inflammation and changes in the naturally existing skin bacteria. CHE can seriously affect daily life and mental health as around 70% of people with severe CHE find it hard to do everyday tasks. Currently available treatments often provide only temporary relief, may cause side effects with long-term use, and may need to be injected, highlighting the need for effective and easy-to-use options. Anzupgo was tested in two studies with about 960 people who had moderate to severe CHE. They used either Anzupgo or a placebo cream twice a day for 16 weeks. More people who used Anzupgo had clear or almost clear skin (20% and 29%) compared to those who used the fake cream (10% and 7%). In a longer follow-up study, about 30% of patients using Anzupgo continued to see improvement after 36 weeks. Overall, the treatment was well-tolerated. Less than 1% of people reported side effects like mild skin pain, tingling, itching, redness, or skin infections. A few also had low white blood cell counts. Anzupgo, made by the drugmaker Leo Pharma, is a steroid-free cream that works by blocking key signals from specific proteins in the immune system known as JAK, which cause inflammation in the skin when overactivated. This helps reduce flare-ups and relieve symptoms. Patients can easily apply the cream to the affected areas only on their hands and wrists, following their doctor's advice, and avoid touching their mouth and eyes. The FDA advises against using Anzupgo alongside other medications that work in a similar way or suppress the immune system, as this could raise the risk of side effects. People using Anzupgo should also avoid live vaccines right before, during, and shortly after treatment. Breastfeeding women are told not to touch their nipple area after applying the cream to their hands or wrists. Doctors should be informed of any ongoing or frequent infections, as well as any other health conditions that might increase the risk of infection during treatment.
